



Company Overview

Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing cell and gene therapies for serious diseases. Abeona's lead clinical program is EB-101, its investigational autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa in Phase 3 development. The Company's development portfolio features AAV-based gene therapies for ophthalmic diseases with high unmet medical need.

Abeona Therapeutics® Announces ABO-503 Gene Therapy for X-linked Retinoschisis (XLRs) Selected by FDA for Rare Disease Endpoint Advancement (RDEA) Pilot Program

Oct 13 2025, 7:30 AM EDT

Abeona Therapeutics® and Children's Hospital Colorado Announce Newest Treatment Center for ZEVASKYN® Gene Therapy

Oct 8 2025, 7:30 AM EDT

Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Oct 1 2025, 7:30 AM EDT

Stock Overview

Symbol	ABEO
Exchange	Nasdaq
Market Cap	275.88m
Last Price	\$5.38
52-Week	\$3.9328 - \$7.5401

10/17/2025 08:00 PM EDT

Investor Relations

ir@abeonatherapeutics.com

Management Team

Vishwas Seshadri, Ph.D., M.B.A.

Chief Executive Officer, Director

Alison Hardgrove, J.D., M.B.A

Chief People Officer

Brian Kevany, Ph.D.

Senior Vice President, Chief Technical Officer & Chief Scientific Officer

Brendan O'Malley, J.D., Ph.D.

Chief Legal Officer

Madhav Vasanthavada, Ph.D., M.B.A.

Senior Vice President, Chief Commercial Officer & Head of Business Development

Joseph Vazzano

Chief Financial Officer

Megan Callan

Vice President, Head of Quality

Carl Denny

Senior Vice President, Regulatory Affairs

Greg Gin

Vice President, Investor Relations and Corporate Communications

Amanda Moore, MSHS

Vice President, Program Leadership and Clinical Operations

Abeona Therapeutics Inc.

6555 Carnegie Avenue
4th Floor
Cleveland, OH 44103

Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.